EGFR/HER2 in breast cancer: a biological approach for molecular diagnosis and therapy (Q37206247)

18 August 2017

1 reference

title

EGFR/HER2 in breast cancer: a biological approach for molecular diagnosis and therapy (English)

1 reference

18 August 2017

0 references

1 reference

Fernando C Schmitt

3

0 references

author name string

Fernanda Milanezi

series ordinal

1

1 reference

PubMed ID

18598224

18 August 2017

Silvia Carvalho

series ordinal

2

1 reference

18 August 2017

1 July 2008

1 reference

Expert Review of Molecular Diagnostics: new diagnostic technologies are set to revolutionise healthcare

18 August 2017

1 reference

18 August 2017

8

1 reference

18 August 2017

4

1 reference

18 August 2017

417-434

1 reference

Molecular approach to breast cancer treatment

18 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.4.417

Will targeted therapy hold its promise? An evidence-based review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.4.417

Adjuvant trastuzumab therapy for HER2-overexpressing breast cancer: what we know and what we still need to learn

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.4.417

Future options with trastuzumab for primary systemic and adjuvant therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.4.417

The EGF receptor family: spearheading a merger of signaling and therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.4.417

Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.4.417

The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.4.417

Targeting the function of the HER2 oncogene in human cancer therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.4.417

Trastuzumab: triumphs and tribulations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.4.417

Use of trastuzumab for the treatment of early stage breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.4.417

Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.4.417

Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.4.417

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.4.417

Assessment of the HER2 status in breast cancer by fluorescence in situ hybridization: a technical review with interpretive guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.4.417

Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.4.417

The basal subtype of breast carcinomas may represent the group of breast tumors that could benefit from EGFR-targeted therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.4.417

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.4.417

Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.4.417

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.4.417

Evaluation of epidermal growth factor receptor (EGFR) by chromogenic in situ hybridization (CISH) and immunohistochemistry (IHC) in archival gliomas using bright-field microscopy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.4.417

The deaf and the dumb: the biology of ErbB-2 and ErbB-3

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.4.417

ERBB receptors and cancer: the complexity of targeted inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.4.417

ErbBs in mammary development

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.4.417

Oncogenic growth factor receptors: implications for signal transduction therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.4.417

Muc4/Sialomucin Complex, the Intramembrane ErbB2 Ligand, Translocates ErbB2 to the Apical Surface in Polarized Epithelial Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.4.417

The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.4.417

A reciprocal tensin-3-cten switch mediates EGF-driven mammary cell migration

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.4.417

Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.4.417

Expression of c-erbB3 protein in primary breast carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.4.417

EGFR family expression in breast carcinomas. c-erbB-2 and c-erbB-4 receptors have different effects on survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.4.417

ErbB/HER ligands in human breast cancer, and relationships with their receptors, the bio-pathological features and prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.4.417

Targeting HER proteins in cancer therapy and the role of the non-target HER3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.4.417

Growth factor receptors in breast cancer: potential for therapeutic intervention.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.4.417

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.4.417

21 January 2018

The Hallmarks of Cancer

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.4.417

Epidermal growth factor receptor (EGFR) as a target in cancer therapy: understanding the role of receptor expression and other molecular determinants that could influence the response to anti-EGFR drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.4.417

Amplification of the epidermal growth factor receptor in astrocytic tumours by chromogenic in situ hybridization: association with clinicopathological features and patient survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.4.417

EGFR and EGFRvIII expression in primary breast cancer and cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.4.417

Role of protein ubiquitylation in regulating endocytosis of receptor tyrosine kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.4.417

Molecular mechanisms underlying endocytosis and sorting of ErbB receptor tyrosine kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.4.417

Disruption of the Y-box binding protein-1 results in suppression of the epidermal growth factor receptor and HER-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.4.417

Y-box-binding protein 1 confers EGF independence to human mammary epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.4.417

Mutational analysis of the HER2 gene in lung tumors from Caucasian patients: mutations are mainly present in adenocarcinomas with bronchioloalveolar features.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.4.417

Somatic mutations of the HER2 kinase domain in lung adenocarcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.4.417

Yin Yang 1 cooperates with activator protein 2 to stimulate ERBB2 gene expression in mammary cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.4.417

Different mechanisms are implicated in ERBB2 gene overexpression in breast and in other cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.4.417

Hsp90 restrains ErbB-2/HER2 signalling by limiting heterodimer formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.4.417

Estimates of the cancer incidence and mortality in Europe in 2006.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.4.417

Predictive markers in breast cancer--the present

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.4.417

Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.4.417

Molecular portraits of human breast tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.4.417

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.4.417

A gene-expression signature as a predictor of survival in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.4.417

Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.4.417

Estrogen-regulated genes predict survival in hormone receptor-positive breast cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.4.417

Molecular classification system identifies invasive breast carcinoma patients who are most likely and those who are least likely to achieve a complete pathologic response after neoadjuvant chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.4.417

p63, cytokeratin 5, and P-cadherin: three molecular markers to distinguish basal phenotype in breast carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.4.417

Metaplastic breast carcinomas exhibit EGFR, but not HER2, gene amplification and overexpression: immunohistochemical and chromogenic in situ hybridization analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.4.417

Phenotypic characterization of BRCA1 and BRCA2 tumors based in a tissue microarray study with 37 immunohistochemical markers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.4.417

Metaplastic breast carcinomas are basal-like tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.4.417

Breast carcinoma with basal differentiation: a proposal for pathology definition based on basal cytokeratin expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.4.417

Triple negative tumours: a critical review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.4.417

Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.4.417

P-cadherin expression in breast cancer: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.4.417

Basal phenotype identifies a poor prognostic subgroup of breast cancer of clinical importance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.4.417

Basal-like breast carcinomas: clinical outcome and response to chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.4.417

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.4.417

Basal-HER2 phenotype shows poorer survival than basal-like phenotype in hormone receptor-negative invasive breast cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.4.417

Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.4.417

Standardization of HER2 testing: results of an international proficiency-testing ring study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.4.417

American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.4.417

retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil:

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.4.417

Amplification and deletion of topoisomerase IIalpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.4.417

Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.4.417

Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer--a study from the IMPACT trialists

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.4.417

Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.4.417

Ductal carcinoma in situ with basal-like phenotype: a possible precursor to invasive basal-like breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.4.417

P-cadherin and cytokeratin 5: useful adjunct markers to distinguish basal-like ductal carcinomas in situ.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.4.417

Identification of a basal-like subtype of breast ductal carcinoma in situ

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.4.417

A mouse model of basal-like breast carcinoma with metaplastic elements

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.4.417

The basal phenotype of BRCA1-related breast cancer: past, present and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.4.417

BRCA1, a potential predictive biomarker in the treatment of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.4.417

EGFR gene amplification in breast cancer: correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.4.417

Independent prognostic value of the basal-like phenotype of breast cancer and associations with EGFR and candidate stem cell marker BMI-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.4.417

Epidermal growth factor receptor expression correlates with poor survival in patients who have breast carcinoma treated with doxorubicin-based neoadjuvant chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.4.417

Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.4.417

Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.4.417

Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.4.417

Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.4.417

Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.4.417

Epidermal growth factor receptor mutations in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.4.417

The role of the epidermal growth factor receptor in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.4.417

External quality assurance of HER2 fluorescence in situ hybridisation testing: results of a UK NEQAS pilot scheme

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.4.417

HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.4.417

Quantitative justification of the change from 10% to 30% for human epidermal growth factor receptor 2 scoring in the American Society of Clinical Oncology/College of American Pathologists guidelines: tumor heterogeneity in breast cancer and its impl

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.4.417

Phosphorylated/activated HER2 as a marker of clinical resistance to single agent taxane chemotherapy for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.4.417

HER2 evaluation using the novel rabbit monoclonal antibody SP3 and CISH in tissue microarrays of invasive breast carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.4.417

A modified Trastuzumab antibody for the immunohistochemical detection of HER-2 overexpression in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.4.417

Patients with advanced stage breast carcinoma immunoreactive to biotinylated Herceptin are most likely to benefit from trastuzumab-based therapy: an hypothesis-generating study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.4.417

Identification of ADAM10 as a major source of HER2 ectodomain sheddase activity in HER2 overexpressing breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.4.417

Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.4.417

Adjuvant endocrine therapy in hormone receptor-positive postmenopausal breast cancer: evolution of NCCN, ASCO, and St Gallen recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.4.417

Fluorescence in situ hybridization (FISH) as primary methodology for the assessment of HER2 Status in adenocarcinoma of the breast: a single institution experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.4.417

Dual-colour chromogenic in situ hybridization for testing of HER-2 oncogene amplification in archival breast tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.4.417

Chromogenic and fluorescent in situ hybridization in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.4.417

Comparison of automated silver enhanced in situ hybridisation (SISH) and fluorescence ISH (FISH) for the validation of HER2 gene status in breast carcinoma according to the guidelines of the American Society of Clinical Oncology and the College of A

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.4.417

Gefitinib (ZD1839) combined with weekly epirubicin in patients with metastatic breast cancer: a phase I study with biological correlate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.4.417

Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: a double-blind placebo-controlled phase II randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.4.417

A multicentre phase II study on gefitinib in taxane- and anthracycline-pretreated metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.4.417

Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.4.417

A mechanistic perspective of monoclonal antibodies in cancer therapy beyond target-related effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.4.417

Antibodies to the epidermal growth factor receptor in non small cell lung cancer: current status of matuzumab and panitumumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.4.417

Continuous cultures of fused cells secreting antibody of predefined specificity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.4.417

Resistance to an irreversible epidermal growth factor receptor (EGFR) inhibitor in EGFR-mutant lung cancer reveals novel treatment strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.4.417

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.4.417

Adjuvant therapy with trastuzumab for HER-2/neu-positive breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.4.417

Herceptin: mechanisms of action and resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.4.417

Breast cancer expressing the activated HER2/neu is sensitive to gefitinib in vitro and in vivo and acquires resistance through a novel point mutation in the HER2/neu

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.4.417

Overview of tyrosine kinase inhibitors in clinical breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.4.417

EGFR associated expression profiles vary with breast tumor subtype

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.4.417

Short preoperative treatment with erlotinib inhibits tumor cell proliferation in hormone receptor-positive breast cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.4.417

HER2 therapy: molecular mechanisms of trastuzumab resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.4.417

Mechanisms of trastuzumab resistance and their clinical implications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.4.417

Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.4.417

Evaluation of serum HER2 extracellular domain in early breast cancer patients: correlation with clinicopathological parameters and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.4.417

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.4.417

PTEN activity could be a predictive marker of trastuzumab efficacy in the treatment of ErbB2-overexpressing breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.4.417

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.4.417

Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.4.417

Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.4.417

Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.4.417

Clinical strategies for rationale combinations of aromatase inhibitors with novel therapies for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.4.417

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.4.417

The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.4.417

Aberrant P-Cadherin Expression: Is it Associated with Estrogen-Independent Growth in Breast Cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.4.417

EGFR amplification and lack of activating mutations in metaplastic breast carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.4.417

Serum HER2 extracellular domain in metastatic breast cancer patients treated with weekly trastuzumab and paclitaxel: association with HER2 status by immunohistochemistry and fluorescence in situ hybridization and with response rate

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.4.417

A Phase I Study of Cetuximab/Paclitaxel in Patients with Advanced-Stage Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.4.417

Hsp90 Recognizes a Common Surface on Client Kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.4.417

21 January 2018

Identifiers

DOI

10.1586/14737159.8.4.417

1 reference

18 August 2017

1 reference

PubMed ID

18598224